We are headquartered in Hyderabad, the pharmaceutical capital of India. We have the expertise in manufacturing APIs since 1984 and PFIs since 1993. We have been marketing our products in the United States since 1987.Granules has posted a sales of about Rs. 180 Crores in 2005-06. Our strategic goal is to offer a complete vertical integrated solution. Offering quality products has helped GIL grow, over the years, to become one of the largest manufacturers of Paracetamol in the world.Granules India Ltd. (GIL) has a long history as a producer of active pharmaceutical ingredients (API's) and pharmaceutical formulation intermediates (PFIs) with complete vertical integration. We support customers with unique value, extensive product range and a global network of associates. Our expertise in manufacturing Pharmaceutical Formulation Intermediates (PFIs), which are Directly Compressible Granules, has helped customers to move to the next level of outsourcing in the pharmaceutical industry. The PFI plant is one of the biggest in the world with an annual capacity of 7200MT and a batch size of 6MT. The plant is approved by USFDA, German Health Authority, Canadian TPD and Australian TGA. GIL is also coming up with a state of the art tableting facility which will have a capacity of 12 Billion tablets. This new tableting facility will be operational by October 2007.Granules makes use of an intelligently integrated production processes in order to manufacture a broad assortment of products, there by supplying a wide range of products and service to our customers in a flexible and reliable manner. Our products can be used in a range of pharmaceutical applications, and we are constantly developing new products and variants to meet our customers' specific requirements.Part of our commitment to the pharmaceutical industry is a high level of customer service: our product specialists, supported by application technologists, research scientists and regulatory advisers are able to provide immediate advice and customer support. By offering unique products and a high level of customer support, we can offer our customers the competitive advantage that is vital in the highly competitive pharmaceutical sector.Our strategy is to adopt a geo-politically neutral stance which reinforces our role as a supply chain partner to our customers. We constantly conduct ourselves in a manner that helps us to fully achieve our self-established standards and further enhance the image of GIL. Our focus is to provide an outsourcing platform for OTC and Rx to OTC drug marketers by positioning ourselves as a strong value added service provider across the value chain.Our Vision is to become a large-scale consumer healthcare focused service provider, with a global presence and infrastructure to support strong partnerships with industry leaders.